Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Okyo Pharma Limited ADR (OKYO)

Okyo Pharma Limited ADR (OKYO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,112
  • Shares Outstanding, K 28,832
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,270 K
  • 60-Month Beta 0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade OKYO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +14.62%
on 04/12/24
1.5700 -5.10%
on 04/29/24
unch (unch)
since 03/28/24
3-Month
1.1900 +25.21%
on 02/02/24
1.9000 -21.58%
on 03/21/24
-0.0100 (-0.67%)
since 01/30/24
52-Week
0.9201 +61.94%
on 07/12/23
3.2500 -54.15%
on 05/08/23
+0.2300 (+18.25%)
since 04/28/23

Most Recent Stories

More News
S&P Futures Climb Ahead of Key U.S. PPI Data, ECB Decision in Focus

September S&P 500 futures (ESU23) are trending up +0.29% this morning after three major U.S. benchmark indices ended the regular session mixed as investors digested the latest U.S. inflation report while...

ESU23 : 4,491.72s (-0.32%)
MRNA : 112.02 (+0.36%)
JBHT : 161.96 (-0.12%)
F : 12.23 (-4.08%)
AAL : 13.59 (-2.79%)
ADBE : 467.97 (-1.08%)
CPRT : 54.68 (-1.85%)
LEN : 153.16 (-1.49%)
ROO.L.EB : 133.500 (-0.52%)
SMTC : 38.02 (+2.62%)
PCT : 4.77 (-3.83%)
MET : 71.40 (-0.42%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.4700 (+0.64%)
ALC : 77.73 (-1.26%)
BLCO : 14.77 (-2.31%)
JNJ : 145.63 (-0.81%)
RHHBY : 30.0300 (-0.99%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.4700 (+0.64%)
ALC : 77.73 (-1.26%)
BLCO : 14.77 (-2.31%)
JNJ : 145.63 (-0.81%)
RHHBY : 30.0300 (-0.99%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

OKYO : 1.4700 (+0.64%)
OKYO.LN : 1.400 (-24.32%)
NVS : 97.30 (+0.22%)
ALDX : 4.00 (-1.23%)
OCUL : 4.88 (+1.67%)
EYPT : 17.21 (-2.38%)
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

/PRNewswire/ -- The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the...

OKYO : 1.4700 (+0.64%)
NVS : 97.30 (+0.22%)
ALDX : 4.00 (-1.23%)
OCUL : 4.88 (+1.67%)
EYPT : 17.21 (-2.38%)
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022...

OKYO : 1.4700 (+0.64%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing

LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing...

OKYO : 1.4700 (+0.64%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing

LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and...

OKYO : 1.4700 (+0.64%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused...

OKYO : 1.4700 (+0.64%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)
OKYO Pharma Limited - PDMR Dealing

LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and...

OKYO : 1.4700 (+0.64%)
EMMLF : 0.0137 (-32.51%)
OKYO.LN : 1.400 (-24.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

OKYO Pharma Limited is a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain. OKYO Pharma Limited is based in LONDON.

See More

Key Turning Points

3rd Resistance Point 1.6429
2nd Resistance Point 1.6065
1st Resistance Point 1.5335
Last Price 1.4700
1st Support Level 1.4241
2nd Support Level 1.3877
3rd Support Level 1.3147

See More

52-Week High 3.2500
Fibonacci 61.8% 2.3600
Fibonacci 50% 2.0851
Fibonacci 38.2% 1.8101
Last Price 1.4700
52-Week Low 0.9201

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar